Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 9:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 1,279 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infection Prophylaxis Clear all

Conditions: Sars-CoV-2 Infection
Interventions: Peginterferon lambda alfa-1a subcutaneous injection, Saline; Drug · Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hantavirus Pulmonary Infection, Immunisation
Interventions: Andes virus DNA vaccine, Placebo; Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Chronic Hepatitis B
Interventions: Tenofovir disoproxil fumarate (tenofovir DF; TDF), Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), Entecavir (ETV), TDF placebo, FTC/TDF placebo, ETV placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 9
States / cities: Los Angeles, California • San Francisco, California • Miami, Florida + 5 more

Conditions: Surgical Site Infection
Interventions: Ertapenem, Cefazolin and Metronidazole.; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infection
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 90 Years
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pregnancy, Sexually Transmitted Infections
Interventions: BUtiful., DIVAS.; Behavioral
Lead sponsor: Tulane University Health Sciences Center; Other
Eligibility: 18 Years to 19 Years · Female only
Enrollment: 637 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 6
States / cities: New Orleans, Louisiana

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Solid Neoplasm
Interventions: Nozin, Best Practice; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Orland Park, Illinois • Seattle, Washington

Conditions: Human Immunodeficiency Virus, HIV Infections
Interventions: EnvDNA; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years to 40 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
Interventions: Posoleucel (ALVR105), Placebo; Biological
Lead sponsor: AlloVir; Industry
Eligibility: Not listed
Enrollment: 451 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 35
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Duarte, California + 31 more

Conditions: HIV Infections, Crack Cocaine Use, Risky Sexual Behavior
Interventions: Prevention Care Advocate; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2011
U.S. locations: 2
States / cities: Miami, Florida • Atlanta, Georgia

Conditions: COVID-19, SAR
Interventions: CBDRA60 supplement, Placebo; Dietary Supplement
Lead sponsor: Anewsha Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Hanover, Michigan

Conditions: Healthy Participants
Interventions: Influenza virus vaccine, Vitamins A and D, Placebo; Biological · Dietary Supplement · Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 2 Years to 8 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: HIV Infections, Sexually Transmitted Diseases
Interventions: PrEPmate, Dot Diary; Other · Device
Lead sponsor: Public Health Foundation Enterprises, Inc.; Other
Eligibility: 15 Years and older
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: San Francisco, California • Washington D.C., District of Columbia • Miami, Florida

Conditions: Hiv
Interventions: FTC/TAF; Drug
Lead sponsor: Philadelphia Fight; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: HIV Infections
Interventions: EnvDNA, PolyEnv1, EnvPro; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hepatitis C, Transplantation Disease Transmission
Interventions: Sofosbuvir/Velpatasvir, Sofosbuvir/Velpatasvir/Voxilaprevir; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 6
States / cities: San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions: MK-8527, LNG/EE; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Infection
Interventions: Voriconazole; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Coronavirus Disease (COVID-19)
Interventions: Molnupiravir, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 2,441 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 59
States / cities: Birmingham, Alabama • Mesa, Arizona • Tucson, Arizona + 53 more

Conditions: Obesity, Obesity, Morbid, Pregnancy, Infection; Cesarean Section
Interventions: Cefazolin; Drug
Lead sponsor: MemorialCare Health System; Other
Eligibility: Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Long Beach, California • Orange, California

Conditions: Influenza A
Interventions: Influenza A H7N7 vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Opioid Use, Opioid-use Disorder, Risk Reduction, Hiv
Interventions: Suboxone, PrEP; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 3
States / cities: Charlotte, North Carolina • Durham, North Carolina • Wilmington, North Carolina

Conditions: Pregnancy
Interventions: influenza and general health information, general health information; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 14 Years to 50 Years · Female only
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Hepatitis C, Hepatocellular Carcinoma
Interventions: Mailed Outreach; Behavioral
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Search by objective public record fields.

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection

Andes Virus DNA Vaccine for the Prevention of Hantavirus Pulmonary Syndrome Using the PharmaJet Stratis(R) Needle-Free Injection Delivery Device

Study Comparing Tenofovir Disoproxil Fumarate (TDF), Emtricitabine (FTC)/TDF, and Entecavir (ETV) in the Treatment of Chronic HBV in Subjects With Decompensated Liver Disease.

PRevention Of Trauma-related Infections Through an Embedded Clinical Trials Network

Antibiotic Prophylaxis Before Percutaneous Gastrostomy

e-SiHLE: An Internet Pregnancy Prevention for Older Teenage Girls

Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY

Evaluate Tolerability of a Recombinant DNA HIV-1 Vaccine in Healthy Adults

Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Project Hope: Hospital Visit is an Opportunity for Prevention and Engagement With HIV-positive Crack Users

(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

Influenza Virus Vaccine Plus Vitamin A and D Supplements for Prevention of Respiratory Virus Infections in Children

Comparing Mobile Health Strategies to Improve Pre-exposure Prophylaxis Use (PrEP) for HIV Prevention

Validation of a Urine Assay to Measure Tenofovir Levels in Patients Taking Tenofovir Alafenamide

Evaluate Tolerability of a Multi-envelope, Prime-boost HIV Vaccine in Healthy Adults

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant

A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)

Voriconazole as Prophylactic Therapy in Lung Transplant Recipients

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

Increased Cefazolin During Cesarean Delivery in Obese Population

Safety and Immunogenicity of Live Influenza A Vaccine for Avian Influenza H7N7

Providing Suboxone and PrEP Using Telemedicine

Influenza and Text Messaging in Pregnancy

STOP HCC: Mailed HCV Treatment Outreach Program for HCC Prevention for Elevated LFTs